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57) ABSTRACT 
Nylon coated microcapsules containing hydrophilic 
solvent-soluble anionic, cationic or quaternary drug 
salts were prepared by interfacial polycondensation 
techniques. In a first stage, the drug substance to be 
encapsulated is dissolved in an aqueous phase. Examples 
of drugs encapsulated are morphine sulfate, diphenhy 
dramine hydrochloride, and methantheline bromide. 
Next the aqueous drug solution is dispersed in an or 
ganic phase. In a second stage complementary polycon 
densation reactants each in an organic phase are added 
separately, either sequentially or simultaneously, to the 
dispersion prepared in the first stage. Microcapsules of 
nylon form around the hydrophilic solvent soluble core 
drug substance. 
10 Claims, 2 Drawing Figures 
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BACKGROUND OF THE INVENTION 
The present invention relates to a process for micro 
encapsulation of hydrophilic core materials utilizing 
interfacial polycondensation techniques. 
The encapsulation of core substances by interfacial 
polycondensation has been widely used in the pharma 
ceutical, agricultural, dye, paint, and carbonless paper 
industries. Microencapsulation is a process whereby 
small particles of core materials such as liquids, solids, 
solutions, or dispersions are thinly coated by a separate 
material. Microencapsulation is often used to improve 
certain physical characteristic of formulations such as 
compressibility and flow. In addition, microencapsula 
tion has been utilized to modify chemical release, to 
improve chemical stability, and to permit the mixing 
and storage of reactive or incompatible materials. 
The principle of the microencapsulation method lies 
in bringing into contact a first liquid phase containing 
the core material to be encapsulated and a polyconden 
sation reagent, with another liquid phase which is im 
miscible with the first phase and contains a second rea 
gent capable of reacting with the first to give a polycon 
densation product. When the two phases are brought 
into contact, the two condensation reagents react at the 
interface of the phases, and by polycondensation, a wall 
of polymer forms around the drops of liquid core mate 
rials. The capsules obtained can then be washed and 
dried before use. 
Various particular methods for carrying out this gen 
eral technique have been proposed. One method con 
sists of carrying out the dispersion and reaction simulta 
neously. For example, in a first stage, an aqueous phase 
is prepared which contains the core substance to be 
encapsulated generally dissolved in a solvent together 
with a hydrophilic polycondensation reagent. This first 
phase is then dispersed in an organic phase containing a 
hydrophobic polycondensation reagent. In this tech 
nique, the polycondensation reaction takes place at the 
actual moment of dispersion. Because the polyconden 
sation and dispersion reactions occur simultaneously, 
microcapsules having an excessively wide distribution 
of diameters result. 
In order to overcome this disadvantage, another 
technique features carrying out the process in two 
stages so as to separate the dispersion operation from 
the polycondensation reaction. For example, U.S. Pat. 
No. 3,522,346 to Chang, provides a process of encapsu 
lating aqueous core substances in microcapsules having 
controlled size, thickness, and permeability. Droplets of 
an aqueous phase containing the core substance to be 
encapsulated together with the hydrophilic polycon 
densation reagent are dispersed in an organic phase. 
Next the hydrophobic polycondensation reagent is 
added to the dispersion thereby producing a polymer 
ized microcapsule by interfacial condensation. 
Initially polymer formation is rapid. However after 
the initial membrane is deposited, further polymeriza 
tion is limited by the rate of diffusion of the hydrophilic 
polycondensation reactant into the organic solvent. 
Unfortunately as a consequence many of the microcap 
sules formed by this method are not easily recovered as 
a dry powder and tend to coalesce to form larger aggre 











generally limited to anionic substances due to pH con 
straints of the aqueous phase. 
In the utilization of interfacial polymerization tech 
niques to encapsulate hydrophilic core materials, a par 
ticularly serious limitation has been encountered in the 
types of materials that are amenable to encapsulation. 
Specifically, the polycondensation monomer included 
in the aqueous phase poses certain pH constraints which 
affect the interfacial partitioning and pH stability of the 
selected core material to be encapsulated. For example, 
microencapsulation of quaternary drugs such as me 
thantheline bromide and benzalkonium chloride has 
been heretofore generally unsuccessful. Further, micro 
encapsulation of xanthine drugs and cationic drugs has 
generally resulted in low yield of encapsulated drug 
generally due to partitioning of the drug into the or 
ganic phase. In some instances degradation of the core 
material is observed and may be attributed to the pH 
conditions of the core influenced by residual monomer 
in the aqueous phase after polymerization is complete. 
The problems discussed above can generally be at 
tributed to the polycondensation monomer included in 
the aqueous phase to be microencapsulated. If the pH of 
the aqueous core can be controlled, then a much greater 
control over drug solubility, partitioning and stability 
can be established for the particular core material to be 
encapsulated. The present invention provides a process 
for microencapsulating a hydrophilic core material 
which overcomes many of the problems encountered 
with prior methods. 
SUMMARY OF THE INVENTION 
The present invention provides a process for the 
microencapsulation of a hydrophilic core material by 
interfacial polycondensation. 
The process involves preparing, in a first stage, a 
dispersion of a continuous hydrophobic phase in a dis 
continuous hydrophilic phase containing the hydro 
philic core material to be encapsulated. The hydrophilic 
core material is generally selected from chemically or 
biologically active substances. Such substances can be 
anionic, cationic, quaternary, or amphoteric salts as 
well as nonionic substances. Examples of materials to be 
encapsulated include drug substances, proteins, en 
zymes, living tissues or cells, inks, dyes, herbicides, etc. 
In a second stage, interfacial polycondensation is 
induced by adding separately, either simultaneously or 
sequentially each of two complementary polycondensa 
tion monomers to the dispersion. One of the monomer 
components is a hydrophobic polycondensation reac 
tant, for example multifunctional acid halides, diacids, 
diisocyanates and multifunctional sulfonyl halides and 
mixtures thereof. The other monomer component com 
prises a hydrophilic polycondensation reactant dis 
persed in a continuous hydrophobic solvent. Examples 
of hydrophilic polycondensation reactants include 
polyfunctional amines, polyols, diamines, diols, and 
other well known polycondensation system reactants. 
Examples of some polymers formed by interfacial 
polymerization, which are useful in microencapsulation 
techniques of this invention include: 
MONOMERS 
POLYMER AQUEOUS-SOLUBLE ORGANIC-SOLUBLE 
polyamide diamine diacid halide 
polyurethane diamine bischloroformate 





POLYMER AQUEOUS-SOLUBLE ORGANIC-SOLUBLE 
polyester glycol diacid halide 
epoxy resin amine epoxy resin 
graft casein styrene/acrylonitrile 
copolymer 
silicone sodium trimethyl- polymer of methyl 
silanolate trimethoxysilane and 
dimethyl silicone 
polyether piperazine 2,2'-dichlorodiethyl 
ether 
polyphenyl- bisphenol acid dichloride 
esters 
polyphthala- diamine phthaloyl dichloride 
mides 
polyphenyl- bisphenol phthaloyl dichloride 
phthalates 
The monomers and resulting polymers are only repre 
sentative and other may be substituted in many cases. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 represents a schematic diagram of an encapsu 
lation method of this invention. 
FIG. 2 represents a general schematic for preparation 
of formalized gelatin microcapsules with a drug, by the 
methods of this invention. 
DETALED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
The invention will be described in terms of preferred 
embodiments which represent the best mode known to 
the Applicants at the time of this application. 
The invention utilizes a variation in the well known 
microencapsulation technique known as interfacial pol 
ymerization. The system generally comprises two mu 
tually immiscible solvents, one being hydrophobic, the 
other being hydrophilic or water. The hydrophilic sol 
vent includes a hydrophilic core material to be encapsu 
lated. A polymer system is selected of the type wherein 
two different monomers undergo a polyaddition or 
polycondensation reaction to form polymer chains 
comprising alternating monomer units. The two reac 
tive monomers must accordingly be at least di-func 
tional, although other polyfunctional monomers may be 
employed to increase the cross-link density of the fi 
nally formed membrane. 
In view of the foregoing, it will be appreciated that a 
number of polymer systems are useable in the process of 
the invention. Thus, while this specification deals pri 
marily with a polyfunctional amine-polyfunctional acid 
halide polymer system, the invention may also be prac 
ticed with, for example, polyols and diacid or diacid 
halide systems to produce polyester membranes; di 
amine and diisocyanate systems to produce a polyurea; 
diols and acid halides and diamines to produce polysul 
fonamides; and other well-known systems which react 
by polycondensation. 
In the process of the invention, the core material to be 
encapsulated is dissolved in a hydrophilic solvent, e.g., 
water, preferably together with an inert carrier material 
Such as gelatin, calcium sulfate, calcium alginate, poly 
vinylpyrrolidone, dextran, polyethylene glycol, ficol, 
hemoglobin, or albumin. The carrier material is selected 
to provide a suitable environment for the reactions 
which the chemically active material to be encapsulated 
undergoes. As a first dispersion, the hydrophilic or 
aqueous phase is mixed with a water immiscible organic 













drophobic solvent forms the continuous phase. The size 
of the droplets determines the size of the microcapsule 
which will be produced. Dispersion may be accom 
plished by any of the well known emulsification tech 
niques such as, for example, using a blender, and may be 
accomplished with the aid of an emulsifying agent. 
When droplets of a desired size have been produced, 
each of a hydrophobic solvent-soluble monomer and a 
second dispersion of hydrophilic solvent-soluble mono 
mer in a hydrophobic phase is introduced into the first 
dispersion. 
Polymerization occurs only at the interface of the 
two-phase system. If sufficient amounts of each mono 
mer are added to the emulsion and the reaction is al 
lowed to proceed to completion, capsule membranes 
are produced which vary in porosity, strength, and 
thickness, and it is difficult or impossible to control the 
reaction so that microcapsules of a given porosity or 
membrane thickness are produced. 
In order that the invention may be more clearly un 
derstood, preferred embodiments will be further de 
scribed in terms of the following examples, which 
should not be constructed to limit the scope of this 
invention. 
EXAMPLE I 
Microencapsulation was first approached by mechan 
ically emulsifying 60 ml of water in 300 ml of organic 
solvent (chloroform/cyclohexane, 1:4). To this was 
added 150 ml of a 0.08 M solution of 1,6-hexane 
thylenediamine (HMD) in the organic solvent (corre 
sponding to 30 ml of 0.4 M aqueous HMD) and 150 ml 
of the organic solvent containing 1.2 ml of sebacyl chlo 
ride (SC). The SC was added first. When the HMD was 
added, slowly at first and then more rapidly, a mass of 
nylon was recovered, and there was no indication that 
anything more than a few microcapsules had formed. 
EXAMPLE II 
A 30 ml of volume of 0.4 M aqueous HMD was 
washed with 300 ml of the organic phase (chloroform 
/cyclohexane, 1:4). The phases were separated and the 
organic phase was used as the source of HMD in an 
attempt to form nylon at an aqueous interface. Again, 60 
ml of water was mechanically emulsified in 300 ml of 
the organic solvent. Then, 1.2 ml of SC was added to 
the stirred emulsion and the 300 ml of washed organic 
solvent was added very slowly at first and then more 
rapidly. Microcapsules were observed to form and no 
nylon was apparent in the organic solvent. This method 
is illustrated in FIG. 1. 
EXAMPLE II 
In order to determine if the present invention does in 
fact meet the goal of producing microcapsules contain 
ing an aqueous core not requiring an alkaline pH, a pH 
4.0 buffer containing bromothymol blue indicator was 
encapsulated. Nylon microcapsules were produced as 
before in EXAMPLE II and there was no change in the 
color of the pH indicator. Therefore, an acidic aqueous 
phase was successfully microencapsulated and the pH 
of the aqueous media remained acidic throughout the 
entire process. 
EXAMPLE IV 
The present example demonstrates that the product 
encapsulated represents only microcapsules containing 
4,518,547 
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the desired aqueous media and that none of the micro 
capsules recovered are actually nylon fragments or 
other objects which may have been produced. These 
uncertainties were approached by microencapsulating 
an aqueous media to which ten drops of the water solu 
ble dye, Adams' Food Color, Lot B-4 were added. 
When the microcapsules were prepared the dye was 
observed to remain only in the newly-formed nylon 
coated microcapsules and was not seen in the bulk or 
ganic solvent. 
After the microcapsules were prepared, 3 samples 
were examined microscopically. Again, the dye was 
observed to remain entirely in the nylon microcapsules. 
There were no pieces of nylon or any dye observed that 
was not microencapsulated. 
EXAMPLE V 
To determine if partitioning of the dye as the union 
ized species might occur, aqueous buffer solutions 
which contained the dye were shaken with the organic 
phase. The pH range of the buffers was from 0.2N HCI 
to 0.2N NaOH. Three intermediate pH buffers and a 
solution of 0.4 M HMD were also equilibrated. The 
process of EXAMPLE II was repeated. In none of the 
cases was the dye observed to partition into the organic 
solvent or to diminish in the intensity of color. 
EXAMPLE VI-X 
Microcapsules were prepared containing no matrix 
material so that the aqueous microencapsulated media 
could be recovered and residual HMD determined. A 
variety of conditions of preparation were studied. In 
EXAMPLE VI, the prior art method of Chang et al. 
Science, 146:524 (1964) and of McGinity et al. J. Pharm, 
Sci. 64: 889 (1975) was used. An aqueous solution of 60 
ml of 0.2 MHMD was emulsified in 300 ml of the or 
ganic solvent and a separate 300 ml portion of the or 
ganic solvent containing 1.2 ml of SC was added. 
EXAMPLE VII involved preparation of the micro 
capsules by the method of the present invention de 
scribed in FIG. 1 and EXAMPLE II-V. A volume of 
60 ml of water was emulsified in 300 ml of the organic 
solvent. Then, 150 ml of organic solvent containing 1.2 








0.08 M. HMD dissolved in the organic solvent. The 45 
HMD was added slowly at first from a separatory fun 
nel, then rapidly. 
EXAMPLE VIII involved preparing microcapsules 
by the method of the present invention, but the concen 
tration of HMD was 0.4 M. The method was the same 
as used in EXAMPLE VII otherwise. 
EXAMPLE IX involved mechanically emulsifying 
60 ml of water in 300 ml of the organic solvent. The SC 
and HMD (each in the organic solvent) were added 
simultaneously, from two separate infusion pumps. 
Therefore, this method of preparation will be referred 
to as the SAR (Simultaneous Addition of Reactants) 
method of interfacial polymerization. Each Harvard 
infusion pump held one 50 ml glass syringe with Teflon 
tubing leading into the sealed system. Both syringes 
were driven at about 2 ml/min for 30 seconds, then 15 
ml/min for 30 seconds and then the remainder was 
delivered at 38 ml/min. One syringe contained 1.2 ml 
SC dissolved in a total of 50 ml of the organic solvent. 
The other syringe contained 50 ml of 0.08M HMD in 
the same solvent. 
EXAMPLE X was carried out identical to EXAM 





7.2X 10.2M. This corresponded to the same amount of 
HMD present in 300 ml of organic solvent washed with 
30 ml of 0.4 M aqueous HMD. , 
Table 2 outlines the duplicate results obtained for 
conditions VI through X: 
Total 
Solvent HMD pH of HMD Concentration 
Example Volume (moles) Media in core 
VI 600 ml 12.0 9.0 1.65 x 10-2M 
10 
VII 600 In 2.0 9.90 440 x 10-2M 
0 
VIII 600 ml 6.05 X 4.05 6.3 x 10-3 M 
10 
IX 400 ml 3.60 k 2.73 8.30 x 10-4M 
10 
X 400 ml 4.00 2.51 9.80 x 10-4 
10 
1.2 ml of SC (5,626 x 10-moles) was used in each case. 
pH after microcapsules were ruptured and diluted to 250 ml. 
In EXAMPLE VI the pH of the aqueous phase after 
the microcapsules were ruptured and diluted to 250 ml 
was 9.01. This alkaline pH indicated that residual HMD 
was present in the core of the microcapsules. This was 
confirmed by the determination of 1.65X10-2M HMD 
inside the microcapsule core (corrected for dilution to 
250 ml). 
Unexpectedly, twice the concentration of HMD was 
found in EXAMPLE VII than in EXAMPLE VI. 
Determination of HMD in the core of microcapsules 
under EXAMPLE VIII demonstrated considerably less 
of the HMD to be present. The total concentration of 
HMD was half that used in EXAMPLE VII, but the 
recovery of HMD from the core was about seven times 
less. Thus, the concentration of residual HMD in the 
microcapsule core is not a linear function of the original 
concentration of HMD. 
Under EXAMPLES IX and X, a considerable de 
crease of the residual HMD in the microcapsule core 
occurred. This is a result of less of the HMD being 
added to the system. Also, the total organic solvent 
volume was reduced from 600 ml to 400 ml. Further, 
the controlled addition of reactants may contribute to 
the decrease in the HMD remaining in the final product. 
The pH of the aqueous media for EXAMPLE IX and X 
was very low, and is a result of HCl being generated by 
the polycondensation reaction. 
Microcapsules produced by the methods described 
under EXAMPLES IX and X were not recovered as 
dry free-flowing powders. Therefore microcapsules 
were prepared which contain a core of either formalde 
hyde-crosslinked gelatin, calcium sulfate or calcium 
alginate. 
EXAMPLE XI 
FIG. 2 illustrates the preparation of nylon microcap 
sules containing a formaldehyde-crosslinked gelatin 
matrix by the methods of the present invention. A me 
chanically stabilized emulsion of 60 ml of aqueous 
media containing 5 gm of gelatin and 2.5gm of drug 
selected from one of morphine sulfate, diphenhydra 
mine hydrochloride, or methantheline bromide was 
formed in 300 ml of the organic solvent. The polycon 
densation reactants were both infused simultaneously at 
the same volume rate. The rates used were described in 
EXAMPLE IX. The gelatin was crosslinked by addi 
tion of 20 ml of formalin (formaldehyde 37%, U.S.P.). 
4,518,547 
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Then, after a total of five minutes had passed since the 
initial addition of reactants had begun, the stirrer was 
stopped and the organic phase was immediately de 
canted from the microcapsules (it was not possible to 
remove more than about 90% of the organic solvent in 
this manner). This slurry was placed in an ice bath for 1 
hour, then dried under a hood at room temperature. 
The formalized gelatin microcapsules were also stud 
ied for the influence of rinsing with different solvents 
and for the effect of varying the time of chilling the 
microcapsules before drying. Immediately after prepa 
ration, the organic solvent was decanted from micro 
capsules as completely as possible. The batch of micro 
capsules was separated into three approximately equal 
portions. One portion was not rinsed, one was rinsed 
with 50 ml of chloroform and the other was rinsed with 
50 ml of carbon tetrachloride. These were all dried 
under a hood at room temperature. Separate batches 
were also prepared and separated into three equal por 
tions. One of the portions was not rinsed, one was rinsed 
with 50 ml of ether and the other portion was rinsed 
with 50 ml of cyclohexane. These were all placed under 
a hood and dried at room temperature. As these dried, 
aggregates were gently broken up with a spatula. Little 
difference was noted in the ease of recovery when the 
microcapsules were rinsed with the solvents described. 
There was no difference observed for microcapsules of 
different batches that were not rinsed. The microcap 
sules that were rinsed with ether were found to dry 
more rapidly than those rinsed with the other solvents 
or not rinsed. No doubt, this is because of the greater 
volatility of ether compared to the other solvents. 
Assay of the microcapsules demonstrated recovery 
greater than 98% for morphine sulfate in microcapsules 
made from each matrix type and for the other drugs in 
the formaldehyde crosslinked gelatin matrix containing 
microcapsules. 
The difference of recovery or morphine sulfate in the 
formalized gelatin microcapsules made by the prior 
method of McGinity et al. and 98-99% recovery in 
those prepared from the present method is significant. 
More impressive is the difference of the diphenhydra 
mine hydrochloride recovery of 56% in prior methods 
and 98% recovery in the present method. 
Previous attempts to microencapsulate quaternary 
compounds (methantheline bromide) had been unsuc 
cessful. Therefore, it was rewarding to find that these 
were easily prepared with the present method. Further 
more, when the microcapsules were viewed under a 
microscope immediately after their preparation, the 
methantheline bromide microcapsules appeared to have 
the most uniform size distribution. 
EXAMPLE XII 
Calcium sulfate matrix-containing microcapsules 
were also prepared by the schematic shown in FIG. 2. 
An aqueous suspension was made to contain 10 gm 
calcium sulfate, 5gm of morphine sulfate and sufficient 
water for a final volume of 20 ml. This was suspended in 
300 ml of the organic solvent by stirring. The reactants 
were infused simultaneously at the same rate from two 
Harvard infusion pumps, each with a 50 ml glass sy 
ringe, as described in EXAMPLE IX. The SC concen 
tration was 0.1125 M and the concentration of HMD 
was 0.08M (this is the initial concentration in the sy 
ringe). After a total of 5 minutes from the initiation of 
the reaction, the stirrer was stopped and the organic 













crocapsules were left under a hood to dry, without any 
agitation for one week. 
EXAMPLE XIII 
Calcium alginate matrix-containing microcapsules 
were prepared as illustrated in FIG. 2. A total of 60 ml 
of aqueous media was prepared to contain 2.5gm of 
sodium alginate and 1.25 gm of morphine sulfate. The 
aqueous media was mechanically emulsified in 300 ml of 
the organic solvent. The reactants were added in two 
separate 50 ml volumes, using infusion pumps as de 
scribed in EXAMPLE IX. The SC concentration was 
0.1125M and the HMD concentration was 0.08M (each 
is given for the 50 ml volume). After the reactants were 
added, 5 ml of saturated aqueous CaC2 solution was 
added. The reaction was continued for a total of 5 min 
utes, then the stirrer was stopped and the microcapsules 
were separated by decanting the organic solvent. The 
microcapsules were dried under a hood at room temper 
ature. 
The calcium alginate and calcium sulfate microcap 
sules were easily recovered as individual particles. The 
calcium alginate microcapsules required a moderate 
amount of attention to insure that the aggregates were 
broken up as the microcapsules dried. However, the 
calcium sulfate microcapsules did not require any atten 
tion for one week. After this time, they were broken up 
gently with a spatula and yielded free-flowing, spherical 
particles very easily. The calcium sulfate and formal 
ized gelatin microcapsules were of approximately the 
same size. However, the calcium alginate microcapsules 
appeared to be several times the size of the others. 
EXAMPLE XIV 
Because the cost of organic solvents and problems 
associated with their disposal are real problems in terms 
of large scale production, a potential method to recover 
and recycle the organic solvent was developed. The 
solvent was washed twice in one fourth of its volume of 
0.1 NHCl, then twice in one fourth of its volume of 0.1 
N HCl with ten percent (v/v) ethanol. This was foll 
lowed by one wash of 0.1 N aqueous NaOH and two 
washings of pure water. One experiment was performed 
using this method on a volume of the organic solvent 
(chloroform/cyclohexane, 1:4) and the same solvent 
was used to prepare four batches of microcapsules by 
the SAR method. The solvent was treated as described 
between each use. There was no difference observed in 
any of the microcapsules of any of the batches. 
While the methods of this invention have been de 
scribed in terms of preferred embodiments, it will be 
apparent to those of skill in the art that various changes 
may be made with the methods described without de 
parting from the scope of the invention, which is de 
fined by the following claims. 
What is claimed is: 
1. A process for the encapsulation of a hydrophilic 
core material in a membrane formed by interfacial poly 
condensation, the process comprising: 
in a first step, dispersing in a first continuous hydro 
phobic phase a hydrophilic phase comprising in 
Solution the hydrophilic material to be encapsu 
lated and a hydrophilic solvent or water; and then 
in a second stage, adding separately to the dispersion 
either sequentially or simultaneously, each of two 
complementary polycondensation monomer reac 
tants: 
4,518,547 
the first polycondensation monomer reactant com 
prising a hydrophobic solvent-soluble reagent; 
the second polycondensation monomer reactant 
comprising a hydrophilic solvent-soluble reagent 
dispersed in a second continuous hydrophobic 
phase; 
allowing the polycondensation monomers to react, 
the reaction effective to cause interfacial polymeri 
zation of a membrane encapsulating the hydro 
philic phase containing the hydrophilic core mate 
rial; and 
separating the encapsulated material from the contin 
uous hydrophobic phase. 
2. The process according to claim 1 wherein the 
hydrophilic core comprises water soluble salts of ani 
onic, cationic, quaternary, amphoteric or nonionic com 
pounds. 
3. The process according to claim 1 wherein the first 
or second continuous hydrophobic phase is a solution of 
cyclohexane and chloroform. 
4. The process according to claim 1 wherein the first 
polycondensation monomer is selected from the group 
10 
consisting of multifunctional acid halides, diacids, diiso 












5. The process according to claim 1 wherein the first 
polycondensation monomer is a multifunctional acid 
halide. 
6. The process according to claim 5 wherein the 
multifunctional acid halide is sebacyl chloride. 
7. The process according to claim 1 wherein the 
second polycondensation monomer reactant is selected 
from the group consisting of polyfunctional amines, 
polyols, diamines, and diols, and mixtures thereof dis 
persed in a hydrophobic continuous phase. 
8. The process according to claim 1 wherein the 
second polycondensation monomer reactant is a di 
amine. 
9. The process according to claim 8 wherein the 
diamine is hexamethylenediamine. 
10. The process according to claim 1 wherein both 
the first and second polycondensation monomer reac 
tants are added simultaneously to the first dispersion. 
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